Allergy/Imm Medical News about Kidney Transplant

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Target of Rapamycin Inhibitors (Sirolimus and Everolimus) for Primary Immunosuppression of Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Trials
Transplantation, 08/28/09

Webster AC et al. – TOR–I have been evaluated in four different primary immunosuppressive algorithms: as replacement for CNI and antimetabolites, in combination with CNI at low and high doses, and with a variable dose of CNI. Generally, surrogate endpoints for graft survival favor TOR–I (lower risk of acute rejection and higher GFR), and surrogate endpoints for patient outcomes are worsened by TOR–I (bone marrow suppression and lipid disturbance). Long–term hard–endpoint data from methodologically robust randomized trials are still required.

<< Previous
Increased Expression of Activation-Induced Cytidine Deaminase is...

Next >>
An Analysis of Factors that Exacerbate Asthma, Based on a...